Fulcrum Therapeutics (FULC) Return on Capital Employed (2019 - 2026)
Fulcrum Therapeutics (FULC) posted quarterly Return on Capital Employed of 29.55% for Q2 2026, up 784.0% year-over-year from 3.34% in Q2 2025, and down 18.34% quarter-over-quarter from 24.97% in Q1 2026.
Fulcrum Therapeutics (FULC) Return on Capital Employed (2019 - 2026) Analysis & Trends
Fulcrum Therapeutics (FULC) has reported Return on Capital Employed for 8 consecutive years, with 29.55% the latest figure, recorded in Q2 2026.
- In Q2 2026, Return on Capital Employed rose 784.0% year-over-year to 29.55%; the TTM figure through Jun 2026 stood at 29.55% (up 784.0% YoY), while the FY2025 annual figure was 28.21%, down 1939.0% from the prior year.
- Return on Capital Employed fell to 29.55% in Q2 2026 per FULC's latest filing, from 24.97% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 5.12% in Q1 2025 and bottomed at 56.33% in Q2 2022.
- Historically, Return on Capital Employed has averaged 34.1% across 5 years, with a median of 38.08% in 2025.
- On a YoY basis, Return on Capital Employed climbed as much as 4289 bps in 2025 and fell as far as 2758 bps in 2025.
- Fulcrum Therapeutics' Return on Capital Employed stood at 51.04% in 2022, then climbed by 15 bps to 43.46% in 2023, then surged by 81 bps to 8.46% in 2024, then sank by 261 bps to 30.54% in 2025, then increased by 3 bps to 29.55% in 2026.
- Business Quant data shows FULC's Return on Capital Employed at 29.55% in Q2 2026, 24.97% in Q1 2026, and 30.54% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Fulcrum Therapeutics | 285.31 Mn | 285.31 Mn | - | -29.55% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -29.55% |
| Mar 31, 2026 | -24.97% |
| Dec 31, 2025 | -30.54% |
| Sep 30, 2025 | -38.77% |
| Jun 30, 2025 | -37.38% |
| Mar 31, 2025 | -5.12% |
| Dec 31, 2024 | -8.46% |
| Sep 30, 2024 | -11.19% |
| Jun 30, 2024 | -13.07% |
| Mar 31, 2024 | -48.01% |
| Dec 31, 2023 | -43.46% |
| Sep 30, 2023 | -40.16% |
| Jun 30, 2023 | -36.35% |
| Mar 31, 2023 | -44.13% |
| Dec 31, 2022 | -51.04% |
| Sep 30, 2022 | -52.29% |
| Jun 30, 2022 | -56.33% |
| Mar 31, 2022 | -43.00% |
| Dec 31, 2021 | -35.85% |
| Sep 30, 2021 | -42.75% |